<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9963">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913405</url>
  </required_header>
  <id_info>
    <org_study_id>261204</org_study_id>
    <nct_id>NCT01913405</nct_id>
  </id_info>
  <brief_title>Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures</brief_title>
  <official_title>A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Innovations GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of BAX 855 in severe
      hemophilia A previously treated (PTP) males, 12 to 65 years of age who are undergoing
      elective surgical or other invasive procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Global Hemostatic Efficacy Assessment score (GHEA)- composed of 3 individual ratings</measure>
    <time_frame>up to 4 weeks post discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>GHEA=Sum of 1-3 ratings, below Excellent: 7-9 (no category &lt;2) Good: 5-7 (no category &lt;1) Fair: 3-4 (no category &lt;1)
Intraoperative hemostasis Excellent=3: Blood Loss (BL) ≤expected for procedure type in non-hemophilic population(NHP)(≤100%) Good=2: BL ≤50% more than expected for procedure type in NHP(101-150%) Fair=1: BL &gt;50% of expected for procedure type in NHP(&gt;150%) None=0: Uncontrolled-requiring rescue therapy
Hemostasis postoperative day 1 Excellent=3: As good or better than expected for type of procedure in NHP Good=2: Probably as good as expected for procedure type in NHP Fair=1: &lt;optimal for procedure type None=0: Uncontrolled-requiring rescue therapy
Postoperative hemostasis after Day 1 with BAX855 at End of Study visit Excellent=3: As good or better than expected for procedure type in NHP Good=2: Probably as good as expected for procedure type in NHP Fair=1: &lt;optimal for procedure type None=0: Uncontrolled after Day 1-requiring rescue therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of inhibitory antibodies to Factor VIII (FVIII)</measure>
    <time_frame>Within 45 days prior to surgery (Screening visit); and End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Immunogenicity assessment using FVIII inhibitor by Nijmegen method. A 72-hour washout period is required prior to immunogenicity tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of binding antibodies to Factor VIII (FVIII), Baxter's PEGylated recombinant FVIII, and polyethylene glycol (PEG)</measure>
    <time_frame>Within 45 days prior to surgery (Screening visit); and End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A 72-hour washout period is required prior to immunogenicity tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of anti-chinese hamster ovary (CHO) antibodies</measure>
    <time_frame>Within 45 days prior to surgery (Screening visit); and End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A 72-hour washout period is required prior to immunogenicity tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of thrombotic events</measure>
    <time_frame>Throughout the study period- please see Outcome Description for more details</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Thrombotic events may occur at any time point throughout the study period and will be reported. Additionally, Thrombotic markers (thrombin-antithrombin III complexes(TAT), D-dimers, fibrinogen, and prothrombin fragment 1.2) will be checked via clinical laboratory assessments at the: screening visit (Within 45 days prior to surgery), Pre-operative visit, Postoperative Day 1, and End of Study Visit (4 weeks after discharge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other investigational product (IP)-related AEs</measure>
    <time_frame>Throughout the study period, within 45 days prior to surgery to 4 weeks after discharge (End of Study Visit)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs - Body temperature</measure>
    <time_frame>Within 45 days prior to surgery;   within 30 - 60 minutes after administration of BAX 855 for pharmacokinetics (PK); preoperatively within 2 hours of surgery; on Day 1, 3, 7 post-surgery; and during End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Body temperature (°C or °F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs - Respiratory rate</measure>
    <time_frame>Within 45 days prior to surgery;   within 30 - 60 minutes after administration of BAX 855 for pharmacokinetics (PK); preoperatively within 2 hours of surgery; on Day 1, 3, 7 post-surgery; and during End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Respiratory rate (breaths/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs - Systolic and Diastolic Blood Pressure (BP)</measure>
    <time_frame>Within 45 days prior to surgery;   within 30 - 60 minutes after administration of BAX 855 for pharmacokinetics (PK); preoperatively within 2 hours of surgery; on Day 1, 3, 7 post-surgery; and during End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Systolic and diastolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs - Pulse Rate</measure>
    <time_frame>Within 45 days prior to surgery;   within 30 - 60 minutes after administration of BAX 855 for pharmacokinetics (PK); preoperatively within 2 hours of surgery; on Day 1, 3, 7 post-surgery; and during End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pulse rate (beats/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in routine laboratory parameters- Hematology</measure>
    <time_frame>Within 45 days prior to surgery (Screening visit); Postoperative Day 1-3 until discharge- whichever is earlier; and End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The hematology panel consists of complete blood count [hemoglobin, hematocrit, erythrocytes (ie, red blood cell count), and leukocytes (ie, white blood cell count)] with differential (ie, basophils, eosinophils, lymphocytes, monocytes, neutrophils) and platelet counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in routine laboratory parameters - Clinical chemistry</measure>
    <time_frame>Within 45 days prior to surgery (Screening visit); Postoperative Day 1 until discharge- whichever is earlier; and End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The clinical chemistry panel consists of sodium, potassium, chloride, bicarbonate, protein, albumin, alanine aminotransferase, bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, and glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative and postoperative blood loss</measure>
    <time_frame>Initiation of the surgery to 24 hours after completion or drain removal, if applicable</time_frame>
    <safety_issue>No</safety_issue>
    <description>Actual intraoperative and postoperative blood loss until drain removal, if applicable, compared to average and maximum blood loss predicted preoperatively for the planned surgery in a hemostatically normal individual of the same sex, age, and stature as the study participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion Requirements</measure>
    <time_frame>From initiation of the surgery to 24 hours after completion of the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The type and volume of blood product utilized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Episodes</measure>
    <time_frame>Intra- and post-operative period, until the time of discharge (minor surgery 1-3 days, major surgery average approximately 2 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any clinically relevant bleeding episodes (as assessed by the investigator), as well as the need for any further surgical interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of BAX855</measure>
    <time_frame>From initiation of the surgery until the time of discharge  (minor surgery 1-3 days, major surgery average approximately 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daily and total weight-adjusted dose of BAX855 per subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of antibodies to murine immunoglobulin G (IgG)</measure>
    <time_frame>Within 45 days prior to surgery (Screening visit); and End of Study Visit (4 weeks after discharge)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A 72-hour washout period is required prior to immunogenicity tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Incremental recovery(IR)</measure>
    <time_frame>Within 30 minutes pre-infusion and post-infusion at, 10 min and 0.5, 1, 3, 6, 9, 24, 32, 48, 56, 72, and 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following at least a 72 hour washout period a single dose of BAX855 will be administered. The PK profiles will be used to guide dosing and dosing frequency during the perioperative time period.
IR= (Concentration(maximum post-infusion)[International Unit(IU)/dL] - Concentration(pre-infusion)[IU/dL]) / Dose[IU/kg]
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Terminal half-life (T1/2)</measure>
    <time_frame>Within 30 minutes pre-infusion and post-infusion at, 10 min and 0.5, 1, 3, 6, 9, 24, 32, 48, 56, 72, and 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following at least a 72 hour washout period a single dose of BAX855 will be administered. The PK profiles will be used to guide dosing and dosing frequency during the perioperative time period.
Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Area under the plasma concentration/time curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>Within 30 minutes pre-infusion and post-infusion at, 10 min and 0.5, 1, 3, 6, 9, 24, 32, 48, 56, 72, and 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following at least a 72 hour washout period a single dose of BAX855 will be administered. The PK profiles will be used to guide dosing and dosing frequency during the perioperative time period.
(AUC0-∞) is calculated as the sum of AUC from time 0 to the time of last quantifiable concentration using the linear trapezoidal rule plus a tail area correction.
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Mean residence time (MRT)</measure>
    <time_frame>Within 30 minutes pre-infusion and post-infusion at, 10 min and 0.5, 1, 3, 6, 9, 24, 32, 48, 56, 72, and 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following at least a 72 hour washout period a single dose of BAX855 will be administered. The PK profiles will be used to guide dosing and dosing frequency during the perioperative time period.
The MRT in hours is calculated as total area under the moment curve divided by the total area under the curve
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Clearance (CL)</measure>
    <time_frame>Within 30 minutes pre-infusion and post-infusion at, 10 min and 0.5, 1, 3, 6, 9, 24, 32, 48, 56, 72, and 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following a 72 hour washout period a single dose of BAX855 will be administered. The PK profiles will be used to guide dosing and dosing frequency during the perioperative time period.
CL in dL/(kg*h) is calculated as the dose in IU/kg divided by the total AUC
h = hours
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Apparent volume of distribution at steady state (Vss)</measure>
    <time_frame>Within 30 minutes pre-infusion and post-infusion at, 10 min and 0.5, 1, 3, 6, 9, 24, 32, 48, 56, 72, and 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following at least a 72 hour washout period a single dose of BAX855 will be administered. The PK profiles will be used to guide dosing and dosing frequency during the perioperative time period.
Vss in dL/kg is calculated as MRT [h] * CL [dL/(kg*h)]
h = hours
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) - Area under the plasma concentration/time curve from time 0 to 96 hours post-infusion (AUC0-96h)</measure>
    <time_frame>Within 30 minutes pre-infusion and post-infusion at, 10 min and 0.5, 1, 3, 6, 9, 24, 32, 48, 56, 72, and 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following at least a 72 hour (h) washout period a single dose of BAX855 will be administered. The PK profiles will be used to guide dosing and dosing frequency during the perioperative time period.
Computed using the linear trapezoidal rule. For the calculation of AUC0-96h the levels at 96 hours will be linearly interpolated from the 2 nearest sampling time points or extrapolated from the last quantifiable concentration.
PK evaluations must be repeated if:
Bleeding episode occurs prior to a 72-hour time point.
≥2 PK blood sample results are not evaluable.
&gt;60 calendar days between the 96 hour post-infusion time point and the planned surgery elapse.
However, if participants enter study from other BAX855 studies, exceptions may be approved by the medical director.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>BAX855</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.
Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant factor VIII (rFVIII)</intervention_name>
    <arm_group_label>BAX855</arm_group_label>
    <other_name>BAX 855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant requires an elective major or minor surgical, dental or other invasive
             procedure (e.g. biopsy, endoscopy).

          -  Participant and/or legal representative has/have provided signed informed consent.

          -  Participant has severe hemophilia A (Factor VIII (FVIII) level &lt;1%) as confirmed by
             the central lab at screening or a documented FVIII activity level &lt;1%.

          -  Participant was previously treated with FVIII concentrates with ≥150 documented
             exposure days (EDs).

          -  Participant is currently receiving prophylaxis or on-demand therapy with FVIII
             concentrate.

          -  Participant has a Karnofsky performance score of ≥60 at screening.

          -  Participant is human immunodeficiency virus negative (HIV-); or HIV+ with stable
             disease and CD4+ count ≥200 cells/mm^3, as confirmed by central laboratory at
             screening.

          -  Participant is Hepatitis C virus negative (HCV-) by antibody or PCR testing (if
             positive, antibody titer will be confirmed by PCR), as confirmed by central
             laboratory at screening; or HCV+ with chronic stable hepatitis as assessed by the
             investigator.

          -  Participant is willing and able to comply with the requirements of the study
             protocol.

        Exclusion Criteria:

          -  Participant has detectable FVIII inhibitory antibodies (≥0.4 Bethesda Unit (BU) using
             the Nijmegen modification of the Bethesda assay) at screening as determined by the
             central laboratory or at any timepoint prior to screening (≥0.4 BU using the Nijmegen
             modification of the Bethesda assay or ≥0.6 BU using the Bethesda assay).

          -  History of ongoing or recent thrombotic disease, fibrinolysis or disseminated
             intravascular coagulation (DIC).

          -  Participant has a platelet count &lt;100 x 10^9/L, as confirmed by central laboratory at
             screening.

          -  Participant has severe renal impairment (serum creatinine &gt; 2.0 mg/dL), as confirmed
             by central laboratory at screening.

          -  Participant has severe chronic hepatic dysfunction (eg ≥5 X upper limit of normal
             alanine aminotransferase (ALT), as confirmed by the central laboratory at screening,
             or a documented International Normalized Ratio (INR) &gt; 1.5).

          -  Participant has a known hypersensitivity towards mouse or hamster proteins,
             polysorbate 80 or to PEG.

          -  Participant is currently using or has recently (&lt; 30 days) used pegylated drugs
             (other than BAX 855) prior to study participation or is scheduled to use such drugs
             during trial participation.

          -  Participant is currently participating in another clinical drug (other than BAX 855)
             or device study or use of another investigational product or device within 30 days
             prior to study entry.

          -  Participant has a diagnosis of an inherited or acquired hemostatic defect other than
             hemophilia A.

          -  Participant is currently receiving, or scheduled to receive during the course of the
             study, an immunomodulating drug (eg, systemic corticosteroid agent at a dose
             equivalent to hydrocortisone &gt;10 mg/day, or alpha interferon) other than
             anti-retroviral chemotherapy.

          -  Participant has a clinically significant medical, psychiatric, or cognitive illness,
             or recreational drug/alcohol use that, in the opinion of the investigator, would
             affect participant safety or compliance.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitt Abbuehl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Innovations GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eli Taube</last_name>
    <phone>43 1201002471240</phone>
    <email>eli_taube@baxter.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Puget Sound Blood Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SHAT of Oncohaematology Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Bulgaria</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 12, 2014</lastchanged_date>
  <firstreceived_date>June 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
